Dekavil is an immunocytokine consisting of a targeting antibody fused to the anti-inflammatory cytokine interleukin-10 (IL10).
Dekavil has demonstrated an impressive ability to selectively localize to arthritic sites in-vivo, potently inhibiting arthritic progression. Dekavil is expected to be superior to non-conjugated recombinant IL10, a biopharmaceutical which has extensively been tested in Phase II clinical trials in chronic inflammation and which has shown efficacy for the treatment of rheumatoid arthritis.
Dekavil has entered Phase II clinical trials in combination with methotrexate for the therapy of Rheumatoid Arthritis. Dekavil is exclusively in-licensed to Pfizer. Pfizer is pursuing development in IBD in parallel and is the sponsor of IBD related studies. Pfizer and Philogen are working in close collaboration to enable success across indications.
EULAR conferences 2013, 2014, 2015
Doll et al., (2013) Arthritis Res. Ther., 15, R13826, 2344-52;
Schwager et al., (2011) Human Reprod., 26, 2344-52;
Schwager et al., (2009) Arthritis Res. Ther., 11, R142;
Trachsel et al., (2007) Arthritis Res. Ther., 9, R9;
Trachsel et al., (2007) J. Invest. Dermatol., 127, 881-886.